Sentences with phrase «of tumor antigens»

Capacity for substantial genetic payload supports multiple tumor antigens or a combination of tumor antigens and other immune stimulatory molecules, such as checkpoint inhibitors.

Modulation of tumor antigen expression, particularly MHC class I and II is a particularly common component of tumor immune evasion 183.

Low frequencies of tumor antigen - specific cells in the peripheral blood has been a limiting factor in treatment.

Not exact matches

Many tumors release cells with distinctive antigens on their surfaces, and affinity - based techniques can pull these cells out of the blood sample relatively easily.

Currently, rising blood levels of prostate - specific antigen (PSA), a protein made by the prostate gland, are used as indicators of tumor recurrence.

The immune system depends on molecules called T cell receptors on the surface of T cells to recognize and respond to foreign antigens from virus - infected cells, tumors and other threats.

We designed chimeric antigen receptor (CAR) T cells that specifically target podoplanin (PDPN), a key protein for the progression of solid tumors, including GBM.»

Prostate cancer risk groups are assigned based on the prostate biopsy results, which include the Gleason score (GS)-- an indication of how aggressively the tumor cells may behave — and the prostate specific antigen (PSA) level in the patient's blood at the time of diagnosis.

She even found evidence that the devils» immune systems were occasionally performing this interferon - gamma trick themselves: In some instances, tumor cells near the edge of the tumor, in close proximity to white blood cells, showed MHC antigens that cells farther within the tumor mass lacked.

Indeed, after Siddle added a squirt of interferon - gamma — a chemical messenger that activates numerous genes involved in producing MHC antigens — to cells cultured from devil tumors, the MHC genes functioned normally again, and the tumor cells» identity cards showed up, plain as day.

Another version, the CTC - iChip, rapidly isolates CTCs in a way that does not rely on preidentified tumor antigens, allowing capture of cells with gene expression patterns that may be missed by the antibodies used in the HBCTC - Chip.

In collaboration with the group of Valerian Kagan, Ph.D., D.Sc., at the University of Pittsburgh, Gabrilovich and colleagues analyzed in great detail the events that take place in the DCs from tumor - bearing mice models and found that impaired cross-presentation, which occurred in the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surface.

Different classes of MHC molecules exist and are involved in immunity against pathogens and tumor cells as well as the formation of immune tolerance to self - antigens.

One of the 43 began producing a new protein, which the researchers took to be an antibody to the tumor antigen.

The Cancer Vaccine Collaborative is working on treatments that target multiple cancer antigens, which should trigger a more aggressive immune response and increase the odds of defeating tumors.

The remaining one - third of patients, composing a control group, received injections of their own dendritic cells that were not exposed to tumor antigens.

The central idea is to encode an antigen as RNA and inject that into the skin of the patient, whose own cells then produce the protein that triggers an immune response, either to kill tumor cells or to prevent an infection.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

In this study, we examined the effectiveness of a vaccination targeting tumors that produced IL - 15 and its cell surface receptor called IL - 15R - alpha -LRB--RRB- and examined their ability to up - regulate (or increase) immune responses to tumor antigens,» Morris says.

He also studies the mechanisms of antigen presentation to T cells, the impact of immunoregulation on tumor antigen - specific responses, and characterization of the tumor - immune microenvironment.

A relatively new biomarker called prostate - specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Dr. Gnjatic's research focuses on human antigen - specific immune responses to tumor antigens, in an attempt to define new targets for the development of cancer immunotherapies, assess the efficacy of these immunotherapies, and learn why they may fail.

«We had a hunch that rapidly growing tumors can «outgrow» their blood supply, resulting in dead tumor cells that might spill their viral antigens amongst the living cancer cells,» said co-senior study author Arturo Casadevall, chair of Einstein's Microbiology & Immunology department.

Over the past two years, investigators from the Perelman School of Medicine at the University of Pennsylvania have reported results from a human trial in GBM using chimeric antigen receptor (CAR) T cell therapy, through which patients» own T cells were engineered to track down and kill cancer cells that express a tumor - specific protein known as EGFRvIII.

A team led by principal investigator Donald M. O'Rourke, MD, an associate professor of Neurosurgery at Penn, and Marcela Maus, MD, PhD, showed that CART - EGFRvIII cells had an acceptable safety profile, crossed the blood - brain barrier, infiltrated the tumor, and prompted an immune response, resulting in reduction of the EGFRvIII tumor antigen in GBM cells.

Compared to a bolus injection containing the same drugs and antigens (but no scaffold), the 3D vaccine was more effective at preventing tumor growth, with 90 % of mice receiving the 3D vaccine still alive at 30 days compared with only 60 % of mice given the bolus injection.

In a 2009 paper published in Nature Materials, Mooney demonstrated that this could be achieved by loading a porous scaffold — about the size of a dime — with tumor antigen as well as a combination of biological and chemical components meant to attract and activate dendritic cells.

Researchers now think that irradiation sometimes kills tumor cells in a manner that exposes new antigens to T cells, priming them to target other tumor cells that carry them as well, says Wenbin Lin, a chemist at the University of Chicago in Illinois, and one of the authors of the current study.

In the featured article of The Journal of Nuclear Medicine's October issue, German researchers report on their recent clinical experience, which establishes a dosing regimen for actinium - 225 (225Ac)- labeled targeted alpha therapy of patients with prostate specific membrane antigen (PSMA)- positive tumors.

However, the tumor surfaces of certain cancers have antigens, molecules that awaken the immune system and induce it to respond.

We report here the adoptive transfer, to patients with metastatic melanoma, of highly selected tumor - reactive T cells directed against overexpressed self - derived differentiation antigens after a nonmyeloablative conditioning regimen.

However, despite this success, the use of immunotherapy remains limited by the scarcity of tumor - specific antigens — substances that can trigger an immune system response to a particular type of cancer.

The types of tumor that can be particularly responsive to immunotherapy generally happen in older people, or people who have genetic factors that allow their tumors to acquire a lot of mutations — so that the tumor has a lot of different antigens that are recognized by the immunotherapy.

Immunity is key to long - term responses Knowing that the immune system is capable of recognizing distinctive features of cancer cells and launching a T cell attack against those tumor antigens, and that checkpoint blockade removes a roadblock to that attack, it's logical that these drugs should work against many tumor types.

Baltimore, Md. (Embargoed until 12:30 pm EDT on Monday, June 8)-- A relatively new biomarker called prostate - specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Hu14.18 K332A is a laboratory - produced antibody designed to activate the immune response against tumor cells by recognizing and binding to an antigen found on the surface of most neuroblastoma tumor cells.

Pramod Srivastava and Lloyd J. Old identify the human homologue of the mouse tumor rejection antigen gp96.

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

[4] Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell - McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S. Phase I trial of overlapping long peptides from a tumor self - antigen and poly - ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

Using transplantable tumor models expressing antigen in an inducible manner or spontaneous tumor models expressing nominal antigens, we try to decipher whether the tumor is ignored or leads to deletion, anergy or class switch of the specific immune response or generate suppressor T cells.

[i] Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen - experienced tumor - specific cytolytic T lymphocytes.

The serologically unique cell surface antigen of Zajdela ascitic hepatoma is also its tumor - associated transplantation antigen.

High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.

Allison JP, McIntyre BW, Bloch D. Tumor - specific antigen of murine T - lymphoma defined with monoclonal antibody.

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

Steven A. Rosenberg and colleagues at the Surgery Branch of the National Cancer Institute demonstrate that adoptive immunotherapy with CD8 + T cells genetically engineering to recognize the NY - ESO - 1 antigen could induce significant tumor regressions in patients with metastatic synovial sarcoma and melanoma.

This lymphocyte cooperativity led to complete regression of tumors, including their antigen - escape variants.

(PMID: 15657293) Download PDF Lurquin C, Lethé B, Corbière V, Théate I, van Baren N, Coulie PG, Boon T. Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

Antonio Lanzavecchia finds that efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte / macrophage colony - stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P. Somatically mutated tumor antigens in the quest for a more efficacious patient - oriented immunotherapy of cancer.